Do you want to read an article? Please log in or register.
Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials
Diabetes - GeneralLipids
Related content
RECOMMENDED
Type 2 DiabetesLipids
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Cardiovasc Diabetol.
Ray KK, Del Prato S, Müller-Wieland D, Cariou B, Colhoun HM, Tinahones FJ, Domenger C, Letierce A, Mandel J, Samuel R, Bujas-Bobanovic M, Leiter LA
doi: 10.1186/s12933-019-0951-9.
Lipids
Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials
Diabet Med.
Leiter LA, Tinahones FJ, Karalis DG, Bujas-Bobanovic M, Letierce A, Mandel J, Samuel R, Jones PH
doi: 10.1111/dme.13817.
Diabetes - General
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Lancet Diabetes Endocrinol.
Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR
doi: 10.1016/
Diabetes - GeneralType 2 Diabetes
Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial
Diabetes Care.
Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, Peterson ED, Holman RR; TECOS Study Group
doi: 10.2337/dc17-1091.
COMMENTED
Diabetes - General
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Lancet Diabetes Endocrinol.
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG, ODYSSEY OUTCOMES Committees and Investigators.
doi: 10.1016/S2213-8587(19)30158-5.
COMMENTED
Further Publications
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a doubleblind, randomised withdrawal phase
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol.
Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ, Kim JH, Lacroix A, Laplanche A, O'Connell P, Tauchmanova L, Pedroncelli AM, Biller BMK, LINC 3 investigators
doi: 10.1016/S2213-8587(20)30240-0.
COMMENTED
Type 2 Diabetes
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis
Diabetes Obes Metab.
Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine M, Heerspink HL, Wong MG, Ninomiya T, Wada T, Perkovic V
doi: 10.1111/dom.
COMMENTED
Diabetes - GeneralType 2 DiabetesGlycemic Control
A Randomized Clinical Trial of the Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Mild Renal Insufficiency: The CompoSIT-R Study
Diabetes Obes Metab.
Scott R, Morgan J, Zimmer Z, Lam RLH, O'Neill EA, Kaufman KD, Engel SS, Raji A
doi: 10.1111/dom.13473.
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials
Int J Cardiol.
Farnier M, Gaudet D, Valcheva V, Minini P, Miller K, Cariou B
doi: 10.1016/j.ijcard.2016.08.273.